Thyroxine dosage during pregnancy in women with primary hypothyroidism.
OBJECTIVE
To assess whether pregnancy changes the thyroxine requirements of hypothyroid women.


METHODS
A retrospective, longitudinal study.


METHODS
Queen Charlotte's and Chelsea Hospital for Women.


METHODS
32 women referred for antenatal care during 35 pregnancies.


METHODS
Changes in thyroid stimulating hormone (TSH) and free thyroxine (fT4) levels as pregnancy progresses.


RESULTS
In most of the pregnancies (80%), no change in thyroxine dose was required (mean dose 129 micrograms). The mean TSH levels in early (1.8 mU/l) and in late pregnancy (1.5 mU/l) were unchanged (P greater than 0.5). In the remaining pregnancies, thyroxine dose was increased after the first antenatal clinic appointment, on the basis of thyroid function test results, from a mean of 104 micrograms to a mean of 172 micrograms (P less than 0.01). These women had a mean early pregnancy TSH of 12.3 mU/l, which decreased by 95% to 1.3 mU/l (P less than 0.01).


CONCLUSIONS
Most of the hypothyroid patients presenting to an antental booking clinic are well controlled in early pregnancy and will remain so throughout pregnancy. The dose of thyroxine does not need to be changed, and further assessments of thyroid function should not be necessary. It is unlikely that the patients were all 'overtreated' before conception, since they were referred to us by a large number of independent doctors. Women who are under-treated before the pregnancy are likely to require both increased thyroxine dose and further thyroid function assays. They can generally be easily detected, biochemically, at the first hospital visit.
Girling
J C
JC
Queen Charlotte's and Chelsea Hospital for Women, London, UK.
de Swiet
M
M
D000328:Adult; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007037:Hypothyroidism / Q000188:drug therapy*; D008137:Longitudinal Studies; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D012189:Retrospective Studies; D013972:Thyrotropin / Q000032:analysis; D013974:Thyroxine / Q000008:administration & dosage* / Q000032:analysis; D013997:Time Factors
D013972:Thyrotropin; D013974:Thyroxine